Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Aytu BioPharma's total debt was $10.96M at Jun 30, 2026. For fiscal 2026 it was $10.96M, down 14.1% from the year before. The highest annual figure on record is $18.19M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $10.96M | -14.1% |
| FY2025 | Jun 30, 2025 | $12.75M | -15.7% |
| FY2024 | Jun 30, 2024 | $15.13M | -7.5% |
| FY2023 | Jun 30, 2023 | $16.36M | -10.0% |
| FY2022 | Jun 30, 2022 | $18.19M | +8.0% |
| FY2021 | Jun 30, 2021 | $16.85M | +1615.5% |
| FY2020 | Jun 30, 2020 | $982.08K | – |
| FY2019 | Jun 30, 2019 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $10.96M | -14.1% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $11.41M | +0.1% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $11.86M | -25.2% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $12.30M | -25.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $12.75M | -15.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $11.39M | -31.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $15.85M | -1.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $16.56M | +2.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $15.13M | -7.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $16.72M | -33.4% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $16.04M | -27.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $16.12M | +11.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $16.36M | -10.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $25.09M | +75.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $22.05M | +33.9% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $14.49M | -13.1% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $18.19M | +8.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $14.27M | +1433.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $16.47M | +1577.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $16.66M | -4.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $16.85M | +533.0% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $930.42K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $982.08K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $17.40M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $2.66M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $0 | – |
See a number that looks wrong?